Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.59 |
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.53 |
| ▸ | RXRB | P28702 | 3/20 | 0.53 |
| ▸ | RXRG | P48443 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11458931 | 0.89 | PTGS1 (0.69) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL28641469 | 0.85 | NR1H4 (0.71) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL30493868 | 0.85 | NR1H4 (0.71) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL29366514 | 0.85 | NR1H4 (0.71) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL238445 | 0.85 | NR1H4 (0.71) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL28501476 | 0.84 | ESR1 (0.52) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL11437704 | 0.83 | NR1H4 (0.69) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL11045683 | 0.83 | NR1H4 (0.69) | ABCC4LMNAGAATSHRPTGS1 | |
| 2-Naphthylacetic Acid SCHEMBL10453180 | 0.83 | NR1H4 (0.69) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL8451511 | 0.83 | FFAR1 (0.71) | PTGESALOX5AKR1B1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005010202-A2 | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS | LIGAND PHARMACUETICALS INCORPORATED (US) | 2005-02-03 | — | — | WO | claimed |
| US-6903128-B2 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC (US) | 2005-06-07 | — | — | US | disclosed |
| WO-2005010202-A2 | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS | LIGAND PHARMACUETICALS INCORPORATED (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6668527-B2 | Antiinflamamtory agents; autoimmune disease | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-6667331-B2 | For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )-3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-05-29 | — | — | US | disclosed |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1244656-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051487-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, CCR10 | ABCC4 427/4885LMNA 1222/4885GAA 3846/4885 |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, VSIG8 | ABCC4 438/4885LMNA 1126/4885GAA 3841/4885 |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, CCR10, SELPLG | ABCC4 446/4885LMNA 1390/4885GAA 4090/4885 |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELP, SELPLG | ABCC4 209/4885LMNA 1458/4885GAA 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.